# Managing Refractory Diarrhoea in HER2-Positive Breast Cancer
> Clinical case study on managing refractory diarrhoea and Clostridioides difficile in breast cancer patients undergoing TCHP-P chemotherapy.

Tags: oncology, breast-cancer, chemotherapy-side-effects, c-diff, her2-positive, medical-education, colitis
## Oncology Ward Teaching: Refractory Diarrhoea Case Study

## Patient Background
* **Diagnosis:** Middle-aged female, HER2+ Breast Cancer (ER 0%, PR 4%).
* **Treatment:** Neoadjuvant TCHP-P (Docetaxel, Carboplatin, Phesgo).
* **History:** Chronic Grade 2 diarrhoea during chemotherapy cycles.

## Acute Presentation & Initial Management
* **Symptoms:** 15–20 stools/day, fever (38.5°C), hypotension (BP 80/47), tachycardia (HR 120-130).
* **Lab Results:** AKI Stage 3 (eGFR 12), WBC 16.7, CRP 403.
* **Intervention:** Aggressive IV fluids, electrolyte replacement, and IV Ceftazidime.

## Diagnostic Timeline & Complications
* **Day 5-7:** Initial stabilization followed by rising WBC (30.8) and CRP (295) after stepping down antibiotics.
* **Imaging:** CT CAP showed diffuse colitis; AXR showed colonic thickening.
* **Endoscopy:** Flexible sigmoidoscopy confirmed Pseudomembranous colitis.

## Treatment Strategy for C. diff (CDI)
* **Medications:** Switched to Fidaxomicin (12 days + taper), IV Metronidazole, and high-dose oral Vancomycin.
* **Testing Note:** Visual pseudomembranes override negative toxin assays in high-volume secretory diarrhoea.

## Clinical Learning Points
* **Drug Impacts:** Phesgo (HER2/EGFR inhibition) and Docetaxel cause a 'double-hit' gut injury.
* **Infection:** Always exclude CMV colitis and C. diff in oncology patients with persistent diarrhoea.
* **Recovery:** CRP may normalize before clinical symptoms fully resolve.
---
This presentation was created with [Bobr AI](https://bobr.ai) — an AI presentation generator.